Kristel Howell
Acute Care · Des Moines, IANPI 1326344789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,154 of the $3,392 with a category attached, or 63.5%. 17 manufacturers reported payments, led by Beigene USA, Inc. at 26.5% of the total. 2025 is the largest year on record at $1,302, more than ten times the $17 reported in 2021. Among acute care clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $125.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$900
- AbbVie$573
- Pfizer$319
- Gilead$196
- Deciphera Pharmaceuticals Inc.$161
- AstraZeneca$147
- plus $1K from 11 others
What the payments were for
- Consulting fees$1,03130%
- Food & beverage$2,15463%
- Education$2076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 1 | $900 |
| AbbVie | 5 | $573 |
| Pfizer | 3 | $319 |
| Gilead(2 entities) | 2 | $196 |
| Deciphera Pharmaceuticals Inc. | 1 | $161 |
| AstraZeneca | 2 | $147 |
| Seagen Inc. | 2 | $131 |
| Genentech USA, Inc. | 1 | $125 |
| Genentech, Inc. | 2 | $122 |
| Adaptive Biotechnologies Corporation | 1 | $117 |
| E.r. Squibb & Sons, L.L.C. | 1 | $111 |
| Johnson & Johnson | 1 | $109 |
| Bayer | 1 | $107 |
| Amgen | 1 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Regeneron Healthcare Solutions, Inc. | 1 | $65 |
| Kyowa Kirin, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,392 in reported general payments places this provider in the 90th percentile of 104 acute care providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 21 | $308,418 |
| ImbruvicaIbrutinib | 18 | $292,532 |
| BrukinsaZanubrutinib | 11 | $160,636 |
| EliquisApixaban | 28 | $22,626 |
| XareltoRivaroxaban | 17 | $12,355 |
| Letrozole | 89 | $1,348 |
| Anastrozole | 87 | $1,235 |
| Tamoxifen Citrate | 28 | $816 |
| Ondansetron Hcl | 26 | $621 |
| Levofloxacin | 11 | $468 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $433 |
| Acyclovir | 77 | $349 |
| Hydroxyurea | 26 | $337 |
| Dexamethasone | 22 | $259 |
| Oxycodone Hcl | 20 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $147 | $308,41821 claims |
| Beigene USA, Inc.Brukinsa | $900 | $160,63611 claims |
| PfizerEliquis | $319 | $22,62628 claims |
| Johnson & JohnsonXarelto | $109 | $12,35517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 acute care providers in Iowa.
Other acute care in Des Moines
- Michele RenzeDes Moines$5K
- Samantha BoninDes Moines$4K
- Caleb AndersonDes Moines$2K
- Julie SchuckDes Moines$2K
- Julie ShryockDes Moines$1K
- Elizabeth BiggerstaffDes Moines$711
- Selena SampsonDes Moines$365
- Jonna LoxDes Moines$256
- Jodi WilsonDes Moines$229
- Whitney HankenCedar Rapids$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.